NCT04957914View on ClinicalTrials.gov

A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

July 14, 2021

Primary Completion Date

October 17, 2022

Study Completion Date

October 17, 2022

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Insulin Glargine

Administered SC

DRUG

LY3209590

Administered SC

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung, Neuss

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY